Skip to main content

Table 4 Association between human papillomavirus (HPV) seropositivitya and incident lung cancer, adjusted for matching variables

From: Absence of an association of human polyomavirus and papillomavirus infection with lung cancer in China: a nested case–control study

Antibody Cases (n = 200) Controls (n = 200)    Trend Testb
% % OR (95 % CIc) P d OR (95 % CIc) P d
HPV 16
 E6 0.5 1.4 0.39 (0.04–3.79) 0.462 1.17 (0.97–1.43) 0.097
 E7 9.3 7.8 1.22 (0.60–2.47) 0.603 1.06 (0.97–1.15) 0.182
 L1 4.4 3.7 1.17 (0.43–3.21) 0.746 1.04 (0.95–1.15) 0.374
HPV 18
 E6 1.6 1.4 1.18 (0.23–5.93) 0.877 1.02 (0.93–1.13) 0.632
 E7 1.6 1.4 1.18 (0.23–5.93) 0.877 1.06 (0.93–1.21) 0.404
 L1 0.5 1.8 0.29 (0.03–2.66) 0.229 1.00 (0.91–1.11) 0.948
Other high-risk HPV
 31 L1 6.6 8.8 0.72 (0.34–1.53) 0.402 1.00 (0.92–1.09) 0.988
 33 L1 0.5 0.5 1.23 (0.08–20.03) 0.887 1.03 (0.93–1.15) 0.537
 52 L1 34.4 33.6 1.04 (0.68–1.57) 0.883 1.00 (0.90–1.11) 0.989
 58 L1 13.7 12.0 1.17 (0.65–2.10) 0.611 1.03 (0.94–1.12) 0.543
Low-risk HPV
 6 L1 45.4 38.2 1.34 (0.89–2.00) 0.167 1.03 (0.95–1.11) 0.503
 11 L1 20.2 13.8 1.58 (0.93–2.68) 0.097 1.05 (0.97–1.14) 0.229
  1. a Seropositivity defined as >400 MFI (median fluorescence intensity)
  2. b The trend tests estimate the odds ratio for a one unit increase in natural log transformed MFI, adjusted for matched variables
  3. c Nominal (uncorrected) 95 % confidence intervals
  4. d P-values are corrected for multiple comparisons using permutation tests